Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biosci Rep ; 41(1)2021 01 29.
Artigo em Inglês | MEDLINE | ID: mdl-33350432

RESUMO

Millions of people infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been diagnosed with coronavirus infectious disease 2019 (COVID-19). The prevalence and severity of COVID-19 differ between sexes. To explain these differences, we analyzed clinical features and laboratory values in male and female COVID-19 patients. The present study included a cohort of 111 people, i.e. 36 COVID-19 patients, 54 sex- and age-matched common viral community-acquired pneumonia (CAP) patients, and 21 healthy controls. Monocyte counts, lymphocyte subset counts, and alanine aminotransferase (ALT), aspartate aminotransferase (AST), and C-reactive protein (CRP) levels in the peripheral blood were analyzed. Higher Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, monocyte counts, and CRP and ALT levels were found in male COVID-19 patients. Decreased lymphocyte subset counts and proportions were observed in COVID-19 patients, except for the CD3+ and CD8+ T cell proportions. The lower CD4+ T cell proportions and higher CD8+ T cell proportions were observed in male and severe COVID-19 patients and the differences were independent of estrogen level. The CD4+ T cell proportion was negatively associated with the CD8+ T cell proportion in male COVID-19 patients; this correlation was non-significant in females. Our work demonstrates differences between sexes in circulating monocyte counts and CD4+ T cell and CD8+ T cell proportions in COVID-19 patients, independent of estrogen levels, are associated with the clinical manifestations in COVID-19 patients with high specificity.


Assuntos
COVID-19/imunologia , Imunidade Inata , Linfócitos/virologia , Monócitos/virologia , Pneumonia Viral/imunologia , SARS-CoV-2/patogenicidade , Adulto , Alanina Transaminase/sangue , Aspartato Aminotransferases/sangue , Proteína C-Reativa/metabolismo , Relação CD4-CD8 , COVID-19/patologia , COVID-19/virologia , Estudos de Casos e Controles , Infecções Comunitárias Adquiridas , Estradiol/sangue , Feminino , Humanos , Contagem de Leucócitos , Linfócitos/imunologia , Masculino , Pessoa de Meia-Idade , Monócitos/imunologia , Pneumonia Viral/patologia , Pneumonia Viral/virologia , Índice de Gravidade de Doença , Fatores Sexuais
2.
J Clin Lab Anal ; 34(10): e23483, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-32696465

RESUMO

BACKGROUND: Clinical recovery does not mean full recovery. It is necessary to explore the aftereffects of COVID-19 in patients and compare the laboratory features of COVID-19 and other viral pneumonias in the recovery stages. METHODS: Forty-seven cases of COVID-19 and 45 cases of other viral pneumonias (control) were included in this study. The laboratory parameters were compared between COVID-19 and control patients as well as severe and moderate COVID-19 patients from the clinical recovery stage to the 4 weeks postdischarge recovery stage. RESULTS: A higher RDW-CV level and neutrophil percentage and lower levels of total proteins, lymphocytes, eosinophils, and MCH were found in COVID-19 patients compared with those in controls from the clinical recovery to the postdischarge recovery stages. Further analysis showed that decreases in lymphocytes, total proteins, and SOD and elevations in neutrophils, FDP, CRP, and ESR were more common in severe than moderate cases of COVID-19 during hospitalization; however, differences in these indicators, except total proteins, were not observed in the postdischarge recovery stages. Additionally, only 76.9% of COVID-19 patients were positive for IgG antibodies against SARS-CoV-2 in the convalescence stage, and one patient that was negative for specific IgG was reinfected. CONCLUSIONS: This study demonstrated that patients recovering from COVID-19 might need better care than that patients with other viral pneumonias due to the possibility of having poor immunity and nutritional conditions. These findings provide new insights to improve the understanding of COVID-19 and improve care for patients affected by these kinds of pandemics in the future.


Assuntos
Infecções por Coronavirus , Pandemias , Pneumonia Viral , Adulto , Betacoronavirus , Contagem de Células Sanguíneas , COVID-19 , Teste para COVID-19 , Técnicas de Laboratório Clínico , Infecções por Coronavirus/sangue , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/fisiopatologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pneumonia Viral/sangue , Pneumonia Viral/diagnóstico , Pneumonia Viral/epidemiologia , Pneumonia Viral/fisiopatologia , SARS-CoV-2
3.
Psychiatry Res ; 253: 28-32, 2017 07.
Artigo em Inglês | MEDLINE | ID: mdl-28324861

RESUMO

The aim was to identify the effects of early vitamin D supplementation on autism-like behaviors (ASD) induced by valproic acid (VPA, an anti-convulsant and a mood stabilizer) in rats. 10 male Wistar rat pups with prenatal exposure to saline were in control group, and 20 Pups with prenatal exposure to VPA were divided into ASD-N (0.9% saline treated) and ASD-D group (vitamin D 80,000 IU/kg treated) on postnatal day 12. Self-grooming, olfactory habituation/dishabituation, and social interaction tests were conducted to assess social interaction, communication, and repetitive behaviors. Serum 25-hydroxyvitamin D (25(OH)D3) was measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results showed that compared with the control group, the ASD-N group exhibited increased self-grooming, and decreased pinning and serum 25(OH)D3. Furthermore, the repetitive behavior of the ASD-N group exhibited a negative linear relationship with serum 25(OH)D3 on PND 42. In conclusion, early vitamin D supplementation in infant rat with ASD induced by VPA significantly improved development and behavior of rats related with ASD.


Assuntos
Antimaníacos/efeitos adversos , Transtorno Autístico/induzido quimicamente , Comportamento Animal/efeitos dos fármacos , Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente , Ácido Valproico/efeitos adversos , Animais , Suplementos Nutricionais , Modelos Animais de Doenças , Feminino , Relações Interpessoais , Masculino , Gravidez , Ratos , Ratos Wistar , Olfato/efeitos dos fármacos , Comportamento Social , Espectrometria de Massas em Tandem , Vitamina D/administração & dosagem , Vitamina D/análogos & derivados , Vitamina D/sangue
4.
Virol J ; 13: 130, 2016 07 28.
Artigo em Inglês | MEDLINE | ID: mdl-27464503

RESUMO

BACKGROUND: Coxsackievirus A16 (CV-A16), a major etiopathologic cause of pediatric hand, foot, and mouth disease (HFMD) worldwide, has been reported to have caused several fatalities. Revealing the evolutionary and epidemiologic dynamics of CV-A16 across time and space is central to understanding its outbreak potential. METHODS: In this study, we isolated six CV-A16 strains in China's Jilin province and construct a maximum clade credibility (MCC) tree for CV-A16 VP1 gene by the Bayesian Markov Chain Monte Carlo method using 708 strains from GenBank with epidemiological information. The evolution characteristics of CV-A16 VP1 gene was also analysed dynamicly through Bayesian skyline plot. RESULTS: All CV-A16 strains identified could be classified into five major genogroups, denoted by GI-GV. GIV and GV have co-circulated in China since 2007, and the CV-A16 epidemic strain isolated in the Jilin province, China, can be classified as GIV-3. The CV-A16 genogroups circulating recently in China have the same ancestor since 2007. The genetic diversity of the CV-A16 VP1 gene shows a continuous increase since the mid-1990s, with sharp increases in genetic diversity in 1997 and 2007 and reached peak in 2007. Very low genetic diversity existed after 2010. The CV-A16 VP1 gene evolutionary rate was 6.656E-3 substitutions per site per year. CONCLUSIONS: We predicted the dynamic phylogenetic trends, which indicate outbreak trends of CV-A16, and provide theoretical foundations for clinical prevention and treatment of HFMD which caused by a CV-A16.


Assuntos
Enterovirus Humano A/isolamento & purificação , Infecções por Enterovirus/virologia , Proteínas Virais/metabolismo , Teorema de Bayes , China , Enterovirus Humano A/classificação , Enterovirus Humano A/genética , Evolução Molecular , Variação Genética , Humanos , Filogenia , Proteínas Virais/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...